Ketone monoester

Phase 2

VVanderbilt University Medical Center

Ketone monoester is one of 47 therapeutic programs targeting Delirium. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

DeliriumRecruiting

DeliriumPhase 2

Recruiting

Competition

Competitive Landscape

78 competitors in Delirium

#DrugCompanyPhaseTrials

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

58 2

Haldol

DDePuy Orthopaedics

Approved

21 3

Exelon

Novartis

Approved

6 4

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Approved

10 5

Voltaren

Novartis

Approved

1 6

Aleve

Jazz Pharmaceuticals

Approved

1 7

Duragesic

CCephalon

Approved

7 8

Anerem

AAcacia Pharma Ltd

Approved

5 9

Spravato

WWim Janssens

Approved

4 10

Sufenta

LLeaf Vertical Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Delirium

NCT07364162

Clinical

Trials by Indication[1]

Delirium1 trial

Exogenous Ketone Ester Supplementation in ICU Delirium (KETONES ICU)

Recruiting·VVanderbilt University Medical Center·Phase 2·NCT07364162·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ketone monoester. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ketone monoester. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Vanderbilt University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: VVanderbilt University Medical Center

Ketone monoester

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Delirium1 trial

References

Drug Info

Quick Facts

Related News